Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6209-6221

  Hardcastle, Ian R ^a   Ahmed, Shafiq U ^b   Atkins, Helen ^b   Farnie, Gillian ^b   Golding, Bernard T ^a   Griffin, Roger J ^a   Guyenne, Sabrina ^a   Hutton, Claire ^b   Källblad, Per ^c   Kemp, Stuart J ^a   Kitching, Martin S ^a   Newell, David R ^b   Norbedo, Stefano ^a   Northen, Julian S ^a   Reid, Rebecca J ^a   Saravanan, K ^a   Willems, Henriëtte M G ^c   Lunec, John ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c De Novo Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYL 3 (4 CHLOROPHENYL) 3 (3 HYDROXYPROPOXY) 2,3 DIHYDROISOINDOL 1 ONE; 3 (4 CHLOROPHENYL) 3 (4 HYDROXY 3,5 DIMETHOXYBENZYLOXY) 2 PROPYL 2,3 DIHYDROISOINDOL 1 ONE; 3 ALKOXYISOINDOLINONE; ISOINDOLE DERIVATIVE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; METALLATION; PROTEIN PROTEIN INTERACTION; SARCOMA CELL; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MODELS, MOLECULAR; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750133440     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601194     Document Type: Article

References (49)

1. Lane, D. P. Cancer. p53, guardian of the genome. Nature 1992, 358, 15-16.
2. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
3. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237-1245.
4. Fuchs, S. Y.; Adler, V.; Buschmann, T.; Wu, X. W.; Ronai, Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 1998, 17, 2543-2547.
5. OIiner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
6. Chene, P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat. Rev. Cancer 2003, 3, 102-109.
7. Cochran, A. G. Antagonists of protein-protein interactions. Chem. Biol. 2000, 7, R85-R94.
8. Cochran, A. G. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 2001, 5, 654-659.
9. Toogood, P. L. Inhibition of protein-protein association by small molecules: Approaches and progress. J. Med. Chem. 2002,45, 1543-1558.
10. Yin, H.; Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem., Int. Ed. 2005, 44, 4130-4163.
11. Braisted, A. C.; Oslob, J. D.; Delano, W. L.; Hyde, J.; McDowell, R. S.; Waal, N.; Yu, C.; Arkin, M. R.; Raimundo, B. C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 2003, 125, 3714-3715.
12. Yin, H.; Lee, G. I.; Sedey, K. A.; Kutzki, O.; Park, H. S.; Omer, B. P.; Ernst, J. T.; Wang, H. G.; Sebti, S. M.; Hamilton, A. D. Terphenyl-based bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-X-L. J. Am. Chem. Soc. 2005, 127, 10191-10196.
13. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; Schoot, B.; Delettre, G.; Marquette, J. P.; Broto, P.; Jean-Baptiste, V.; Bichet, P.; Sarubbi, E.; Mandine, E. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
14. Zeng, L.; Li, J. M.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C. F.; Wang, Z. Y.; Zhou, M. M. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 2005, 127, 2376-2377.
15. Becattini, B.; Sareth, S.; Zhai, D. Y.; Crowell, K. J.; Leone, M.; Reed, J. C.; Pellecchia, M. Targeting apoptosis via chemical design: Inhibition of bid-induced cell death by small organic molecules. Chem. Biol. 2004, 11, 1107-1117.
16. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
17. Bottger, V.; Bottger, A.; Howard, S. F.; Picksley, S. M.; Chene, P.; Garcia-Echeverria, C.; Hochkeppel, H. K.; Lane, D. P. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996, 13, 2141-2147.
18. Garcia-Echeverria, C.; Chene, P.; Blommers, M. J. J.; Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 2000, 43, 3205-3208.
19. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; Belling, A.; Zeslawski, W.; Kamionka, M.; Rehm, T.; Muhlhahn, P.; Schumacher, R.; Hesse, F.; Kaluza, B.; Voelter, W.; Enhh, R. A.; Holak, T. A. Chalcone derivatives antagonise interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001, 40, 336-344.
20. Zhao, J. H.; Wang, M. J.; Chen, J.; Luo, A. P.; Wang, X. Q.; Wu, M.; Yin, D. L.; Liu, Z. H. The initial evaluation of nonpeptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 2002, 183, 69-77.
21. Majeux, N.; Scarsi, M.; Caflisch, A. Efficient electrostatic solvation model for protein-fragment docking. Proteins 2001,42, 256-268.
22. Duncan, S. J.; Gruschow, S.; Williams, D. H.; McNicolas, C.; Purewal, R.; Hajek, M.; Gerlitz, M.; Martin, S.; Wrigley, S. K.; Moore, M. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 2001, 123, 554-560.
23. Chene, P.; Fuchs, J.; Bohn, J.; Garcia-Echeverria, C.; Furet, P.; Fabbro, D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 2000, 299, 245-253.
24. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
25. Grasberger, B. L.; Lu, T. B.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S. Y.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48, 909-912.
26. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T. E.; Petrella, E. C.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Lu, T. B. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 2005, 15, 765-770.
27. Geiger, T.; Husken, D.; Weiler, J.; Natt, F.; Woods-Cook, K. A.; Hall, J.; Fabbro, D. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides. Anti-Cancer Drug Des. 2000, 15, 423-430.
28. Meye, A.; Wurl, P.; Bache, M.; Bartel, F.; Grunbaum, U.; Mansaard, J.; Schmidt, H.; Taubert, H. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene. Cancer Lett. 2000, 149, 181-188.
29. Chen, L.; Agrawal, S.; Zhou, W.; Zhang, R.; Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 195-200.
30. Wasylyk, C.; Salvi, R.; Argentini, M.; Dureuil, C.; Delumeau, I.; Abecassis, J.; Debussche, L.; Wasylyk, B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999, 18, 1921-1934.
31. Chene, P.; Fuchs, J.; Carena, I.; Furet, P.; Echeverria, C. G. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett. 2002, 529, 293-297.
32. Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Källblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M. G.; Lunec, J. Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg. Med. Chem. Lett. 2005, 15, 1515-1520.
33. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
34. Mancera, R. L.; Källblad, P.; Todorov, N. P. Ligand-protein docking using a quantum stochastic tunneling optimization method. J. Comput. Chem. 2004, 25, 858-864.
35. Källblad, P.; Mancera, R. L.; Todorov, N. P. Assessment of multiple binding modes in ligand-protein docking. J. Med. Chem. 2004, 47, 3334-3337.
36. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
37. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Boehm, H. J.; Dean, P. M. A validation study on the practical use of automated de novo design. J. Comput.-Aided Mol. Des. 2002, 16, 459-478.
38. Kitching, M. S.; Clegg, W.; Elsegood, M. R. J.; Griffin, R. J.; Golding, B. T. Synthesis of 3-alkoxy and 3-alkylamino-2-alkyl-3-arylisoindolinones. Synlett 1999, 997-999.
39. Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y. Z.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Parsons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-based design of 2-arylamino-4- cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
40. Douglas, N. L.; Ley, S. V.; Lucking, U.; Warriner, S. L. Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis. J. Chem. Soc., Perkin Trans. 1 1998, 51-65.
41. Orndorff, W. R.; Murray R. R. A new class of phthaleins-mixed phthaleins-formed by heating p-hydroxy-o-benzoic acids with phenols. J. Am. Chem. Soc. 1917, 39, 679-697.
42. Maple, J. R.; Dinur, U.; Hagler, A. T. Derivation of force-fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.
43. Todorov, N. P.; Dean, P. M. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J. Comput.-Aided Mol. Des. 1997, 11, 175-192.
44. Kallblad, P.; Todorov, N. P.; Willems, H. M. G.; Alberts, I. L. Receptor flexibility in the in silico screening of reagents in the S1′ pocket of human collagenase. J. Med. Chem. 2004, 47, 2761-2767.
45. Firth-Clark, S.; Willems, H. M. G.; Williams, A.; Harris, W. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen. J. Chem. Inf. Comput. Sci. 2006, 46, 642-647.
46. Bondi, A. Van der Waals volumes and radii. J. Phys. Chem. 1968, 65, 441-451.
47. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein ligand complex of known 3-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
48. Todorov, N. P.; Dean, P. M. A branch-and-bound method for optimal atom-type assignment in de novo ligand design. J. Comput.-Aided Mol. Des. 1998, 12, 335-349.
49. Liang, H.; Lunec, J. Characterisation of a novel p53 down-regulated promoter intron 3 of the human MDM2 oncogene. Gene 2005, 361, 112-118.